Fiasse R, Lurhuma A Z, Cambiaso C L, Masson P L, Dive C
Gut. 1978 Jul;19(7):611-7. doi: 10.1136/gut.19.7.611.
Circulating immune complexes were determined in 59 consecutive patients with Crohn's disease and 100 blood donors by a double method based on the inhibition of the agglutinating activity of CIq and/or rheumatoid factor on the IgG-coated polystyrene particles. In patients, the incidence of positive immune complexes was 63% and 61% at first testing, 85% and 78% at subsequent determinations; there was a good correlation between the inhibition titres of CIq and those of rheumatoid factor (p less than 0.001). In blood donors, the incidence was 22% and 14% at low titre. The incidence of immune complexes was the lowest (36%) in the group of resected patients without signs of relapse; repeat determinations showed absence of immune complexes three months postoperatively. In patients medically treated for primary disease or relapse, rheumatoid factor titre higher than 1/1 was less frequent than in medically untreated patients with active disease (p less than 0.01). A significantly higher concentration of serum alpha-1-antitrypsin and orosomucoid, and a significantly lower level of serum iron were found in patients with an IC titre exceeding 1/1; longitudinal studies showed in most cases a concordance between the evolution of immune complex titres, inflammatory parameters and clinical status.
采用一种基于抑制CIq和/或类风湿因子对IgG包被的聚苯乙烯颗粒的凝集活性的双重方法,对59例连续性克罗恩病患者和100名献血者的循环免疫复合物进行了检测。在患者中,首次检测时免疫复合物阳性的发生率分别为63%和61%,随后检测时为85%和78%;CIq的抑制效价与类风湿因子的抑制效价之间存在良好的相关性(p<0.001)。在献血者中,低滴度时发生率分别为22%和14%。在无复发迹象的切除患者组中,免疫复合物的发生率最低(36%);重复检测显示术后三个月无免疫复合物。在接受原发性疾病或复发药物治疗的患者中,类风湿因子效价高于1/1的情况比未接受药物治疗的活动性疾病患者少见(p<0.01)。在免疫复合物效价超过1/1的患者中,血清α1抗胰蛋白酶和类粘蛋白的浓度显著升高,血清铁水平显著降低;纵向研究表明,在大多数情况下,免疫复合物效价、炎症参数和临床状态的变化是一致的。